Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders

@article{Priest1995ReversibleAS,
  title={Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders},
  author={Robert G. Priest and R. Gimbrett and Matthew Roberts and J. Steinert},
  journal={Acta Psychiatrica Scandinavica},
  year={1995},
  volume={91}
}
The clinically tested reversiblc inhibitors of monoamine oxidase A (RIMAs) include brofaromine, moclobemide and toloxatone. Moclobemide has shown unequivocal antidepressant activity against serious deprcssivc illness in 4 placebo‐controlled double‐blind trials. It has been compared with amitriptyline, imipramine, clomipramine, desipramine, maprotiline, fluoxetine, fluvoxamine, tranylcypromine. toloxatone, mianserin and amineptine in the treatment of depressive disorders. Meta‐analysis showed… Expand
Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression
TLDR
The present results suggest that high-activity MAO-A genotypes possibly by consecutively decreased serotonin and/or norepinephrine availability negatively influence antidepressant treatment response during the first six weeks of pharmacological treatment in female patients with Major Depression. Expand
Pharmacological Alternatives to Psychostimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder
TLDR
Central anticholinesterases, such as donepe-zil, may improve core ADHD symptoms and perhaps some associated features that psychostimulants do not—particularly organizational capacity and possibly other executive functions. Expand
4‐fluorotranylcypromine, a novel monoamine oxidase inhibitor: Neurochemical effects in rat brain after short‐ and long‐term administration
A series of acute and chronic experiments was conducted on 4‐fluorotranylcypromine (FTCP), an analog of the monoamine oxidase (MAO)‐inhibiting antidepressant tranylcypromine (TCP) in which the 4Expand
Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
TLDR
These studies revealed marked neurochemical differences among phenelzine, moclobemide and brofaromine which could contribute to their actions in the clinical setting. Expand
Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders
TLDR
The present paper chronicles the discovery and development of psychotropic agents, focusing in particular on their mechanisms of action and therapeutic utility, and how problems faced were eventually overcome. Expand
Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs
TLDR
The behavioural effects of acute and chronic treatments with the reversible monoamine oxidase-A inhibitors (RIMAs) moclobemide and befloxatone in the Mouse Defence Test Battery suggest that befl oxatone may have some efficacy in the clinical management of panic. Expand
A review of the neuropsychological effects of commonly used prescription medications.
  • R. Stein, T. Strickland
  • Psychology, Medicine
  • Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists
  • 1998
TLDR
This review covers the basic science and clinical literature addressing neuropsychological functioning both in healthy nonpatients and in patients treated with antidepressants, anxiolytics, stimulants, antihypertensives, antiepileptics and antihistamines. Expand
Pharmacotherapy Of Selective Mutism: Two Case Studies Of Severe Entrenched Mutism Responsive To Adjunctive Treatment With Fluoxetine
Abstract Selective mutism is a rare psychiatric disorder of unknown aetiology that usually has its onset in early childhood. It appears to be a childhood variant of social phobia, panic or separationExpand
Reviews : Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats
  • E. Garland
  • Medicine
  • Journal of psychopharmacology
  • 1998
TLDR
Based on short- and intermediate-term studies to date, stimulant medication is clearly more efficacious than cognitive and behavioral strategies for the symptoms of ADHD, and indications for long-term stimulant treatment of ADHD present some controversy. Expand
Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats.
A recent increase in stimulant treatment of adolescents with attention deficit hyperactivity disorder (ADHD) has been documented. Challenges in treating adolescent ADHD with methylphenidate orExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders
In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia,Expand
Reversible monoamine oxidase-A inhibitors in panic disorder.
TLDR
A randomized, double-blind, 8-week trial in which the efficacy and safety of brofaromine was compared to clomipramine in patients with panic disorder with or without agoraphobia achieved a significant and comparable reduction in the number of panic attacks. Expand
A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.
TLDR
In the present double-blind study Moclobemide has been compared to placebo in a group of 34 unipolar psychotic or neurotic depressed patients and results have shown that the active drug was markedly superior to placebo. Expand
Moclobemide and the reversible inhibitors of monoamine oxidase antidepressants
  • R. Priest
  • Medicine
  • Acta psychiatrica Scandinavica. Supplementum
  • 1990
TLDR
In all 5 studies comparing moclobemide with imipramine there was no statistically significant difference in efficacy, and the lack of substantial difference suggests that the drugs may well be of similar potency. Expand
Recent advances in antidepressant drugs.
TLDR
Moclobemide is a RIMA that has proved itself to be very effective in severe depressive illness and may be expected to be associated with a high acceptability in depressed patients. Expand
RIMA — A new concept in the treatment of depression with moclobemide
TLDR
Moclobemide, a specific reversible inhibitor of monoamine oxidase that shows a preference for the A isoenzyme, has been developed as a new antidepressive agent that is devoid of any clinically significant tyramine interaction, thus making dietary restrictions during therapy unnecessary. Expand
Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
TLDR
A significant improvement was found on measures of social anxiety, phobic avoidance, general (or anticipatory) anxiety and interpersonal sensitivity in patients on brofaromine, but not on placebo, during a follow-up period of 12 weeks. Expand
Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
TLDR
The therapeutic efficacy of brofaromine--a new reversible and short acting MAO-A inhibitor--was evaluated in 14 patients with a panic disorder and a distinct improvement in both anxiety and depressive symptoms was observed under the active drug. Expand
A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.
TLDR
Patients suffering from a major depressive episode according to DSM-III criteria were randomly allocated to groups receiving either moclobemide, imipramine, or placebo treatment, and the overall assessment of tolerance clearly favoured placebo and moclOBemide over imipramsine. Expand
Biochemical aspects of the pharmacology of moclobemide. The implications of animal studies.
  • B. Callingham
  • Medicine
  • The British journal of psychiatry. Supplement
  • 1989
TLDR
Animal experiments, both in vitro and in vivo, can give realistic indications not only of the mode of action of inhibitors of MAO and any toxicity, but also of the chance of potentially life-threatening hypertensive crises following inadvertent ingestion of amine-containing food or medicaments. Expand
...
1
2
3
4
5
...